Is Aclarion, Inc. (ACON) a Buy, Sell, or Hold?
NASDAQ : ACON
Aclarion, Inc.
$2.305 USD
-$0.06 (-2.33%)
- Volume
- 19.98K
- Average Volume
- 67.35K
- Market Capitalization
- $1.23M
- P/E Ratio
- -0.30
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $12.03
- Year Low
- $1.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $16.20
Company Overview
NASDAQ
Brent Ness
Medical - Healthcare Information Services
Healthcare
ACON
11
US
USD
Liquidity Metrics
0.00
16.20
16.20
15.71
0.00
Sales & Valuation
$75730
14.67
0.33
-0.15
-3.28
Profitability
-$13.61
-$7.23M
-10978.48%
-10978.48%
-59.34%
-50.98%
P/E Metrics
-0.30
0.00
0.00
Analyst Price Target & Rating
2/5
2 Analysts
%
Financial Health Scores
-4.88
2/9
$15.76M
$18.04M
$1.04M
-$9.2M
Key Metrics (TTM)
-$15.03M
-179.38
1.68
16.20
-59.34%
-57.11%
-158.26%
-642.47%
-1912 days
Company Executives
| Name | Title |
|---|---|
| Jeffrey John Thramann | Executive Chairman |
| Brent Ness | Chief Executive Officer, President & Director |
| Gregory A. Gould | Chief Financial Officer |
| Ryan Bond | Chief Strategy Officer |
Poll Results
No votes yet today — be the first to share your view!
About Aclarion, Inc. (NASDAQ:ACON) Stock
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc. ...
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates
2026-08-06 13:01:28
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $2.75 per share a year ago.
2026-08-04 07:05:36
PR Audio: BROOMFIELD, Colo., August 04, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
2026-08-04 07:00:00
Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networks Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research Availability of Nociscan in Indiana reflects Company's focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology.
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
2026-07-29 07:03:10
PR Audio: Broomfield, CO, July 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
2026-07-29 07:00:00
141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S. Continued progress toward the CLARITY trial readout with the addition of multiple new trial sites Strengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwide Strong balance sheet with $16.3M cash and no debt as of June 30, 2026 BROOMFIELD, Colo., July 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company's recent momentum and value creating priorities through the first half of 2026.
2026-07-21 07:04:29
PR Audio: BROOMFIELD, Colo., July 21, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
2026-07-21 07:00:00
Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablation Early findings from real-world evidence study demonstrate immense utility and ability of Nociscan to be incorporated into clinical practice Case study represents first reported use of Nociscan to guide basivertebral nerve ablation in a patient without classic Modic changes on standard MRI, resulting in 95% relief of long-standing chronic low back pain BROOMFIELD, Colo., July 21, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the presentation of two abstracts featuring Nociscan® at the American Society of Pain & Neuroscience (ASPN) Annual Meeting in Miami, Florida.
Aclarion Announces Texas Spine Care Center as New CLARITY Site
2026-07-07 07:01:47
PR Audio: BROOMFIELD, Colo., July 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Frequently Asked Questions
-
What is the current Aclarion, Inc. (ACON) stock price?
-
Aclarion, Inc.(NASDAQ:ACON) stock price is $2.305 in the last trading session. During the trading session, ACON stock reached the peak price of $12.03 while $1.95 was the lowest point it dropped to. The percentage change in ACON stock occurred in the recent session was --2.33% while the dollar amount for the price change in ACON stock was -$0.06.
-
ACON's industry and sector of operation?
-
The NASDAQ listed ACON is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector.
-
Who are the executives of ACON?
-
Jeffrey John Thramann | Executive Chairman
Brent Ness | Chief Executive Officer, President & Director
Gregory A. Gould | Chief Financial Officer
Ryan Bond | Chief Strategy Officer
| -
How many employees does ACON have?
-
Number of ACON employees currently stands at 11. ACON operates from 8181 Arista Place, Broomfield, CA 80021, US.
-
Link for ACON official website?
-
Official Website of ACON is: https://www.aclarion.com
-
How do I contact ACON?
-
ACON could be contacted at phone #650-241-1741 and can also be accessed through its website. ACON operates from 8181 Arista Place, Broomfield, CA 80021, US.
-
How many shares of ACON are traded daily?
-
The average number of ACON shares traded daily for last 3 months was 67.35K.
-
What is the market cap of ACON currently?
-
The market value of ACON currently stands at $1.23M with its latest stock price at $2.305